Skip to main content

Advertisement

Table 2 Antibody titres over 96 weeks of AADvac1 treatment

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

  GMT
Week + 4 Week + 8 Week + 12 Week + 16 Week + 20 Week + 24 Week + 36 Week + 44 Week + 48 Week + 60 Week + 72 Week + 76 Week + 84 Week + 96
Anti-KLH 260.0 8128 36,784 68,023 102,453 127,972 68,870 42,043 30,967 141,323 76,711 172,828 177,672 116,545
(lower CI) 103.4 2763 21,622 45,268 62,490 77,347 47,757 28,870 21,922 101,408 52,550 132,513 158,315 83,702
(upper CI) 653.7 23,906 62,578 102,216 167,973 211,734 99,316 61,225 43,742 196,949 111,982 225,409 199,395 162,275
Anti-peptide IgG 219.1 7318 18,382 26,868 29,047 36,697 16,483 8908 6789 23,541 9541 32,023 17,741 6679
(lower CI) 104.5 3300 10,084 16,320 18,244 22,759 10,642 5233 3913 14,811 5819 20,397 10,941 3580
(upper CI) 459.2 16,228 33,509 44,233 46,246 59,171 25,529 15,163 11,781 37,417 15,646 50,273 28,767 12,462
Anti-peptide IgM 1659 16,586 40,048 66,087 69,789 72,154 29,150 21,702 18,272 37,301 20,904 45,288 29,153 21,018
(lower CI) 596.7 8075 25,606 47,284 49,429 53,114 19,298 13,862 11,250 22,220 11,621 23,581 15,903 10,887
(upper CI) 4612 34,068 62,634 92,366 98,536 98,019 44,032 33,976 29,676 62,616 37,602 86,980 53,443 40,575
  1. Ig Immunoglobulin, KLH Keyhole limpet haemocyanin
  2. Basic vaccination regimen is shown in bold